Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionTd Asset Management Inc
Latest Disclosed Ownership228,195 shares
Latest Disclosed Value $ 101,898,195
Td Asset Management Inc reports 24.96% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 11, 2026 - Td Asset Management Inc filed a 13F-HR form disclosing ownership of 228,195 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $101,898,195 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 182,613 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 24.96% during the quarter. The current value of the position is $100,802,859 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 228,195 45,582 24.96 101,898 23.08 0.0442
2026-02-10 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 182,613 -34,926 -16.06 82,789 -2.83 0.0666
2025-11-10 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 217,539 -247,634 -53.23 85,197 -58.86 0.0692
2025-07-28 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 465,173 -20,683 -4.26 207,095 -12.08 0.1768
2025-05-07 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 485,856 16,788 3.58 235,553 24.70 0.2168
2025-02-11 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 469,068 -53,137 -10.18 188,894 -21.85 0.1671
2024-11-01 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 522,205 18,151 3.60 241,718 2.31 0.2133
2024-08-02 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 504,054 -11,346 -2.20 236,260 9.66 0.2203
2024-05-08 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 515,400 -18,513 -3.47 215,442 -0.83 0.2004
2024-02-12 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 533,913 53,850 11.22 217,244 30.13 0.2136
2023-10-27 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 480,063 103,097 27.35 166,937 25.84 0.2022
2023-08-09 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 376,966 -9,620 -2.49 132,658 8.91 0.1511
2023-05-10 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 386,586 6,572 1.73 121,802 10.99 0.1470
2023-02-07 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 380,014 -59,581 -13.55 109,740 -14.74 0.1354
2022-11-07 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 439,595 -1,946 -0.44 128,713 3.45 0.1612
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 441,541 434,841 6,490.16 124,422 7,017.96 0.1441
2022-05-10 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,700 -323,079 -97.97 1,748 -97.59 0.0010
2022-05-10 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 436,566 113,930
2022-02-10 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 329,779 9,855 3.08 72,420 24.80 0.0606
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 319,924 -25,689 -7.43 58,031 -16.70 0.0602
2021-08-11 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 345,613 -134,074 -27.95 69,669 -32.41 0.0707
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 479,687 -122,706 -20.37 103,080 -27.60 0.1152
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 602,393 -18,348 -2.96 142,370 -15.72 0.1729
2020-11-10 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 620,741 28,773 4.86 168,916 -1.71 0.2343
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 591,968 11,139 1.92 171,854 24.34 0.2445
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 580,829 22,345 4.00 138,208 13.03 0.2339
2020-02-11 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 558,484 -10,495 -1.84 122,280 26.85 0.1775
2019-11-07 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 568,979 31,902 5.94 96,396 -2.13 0.1474
2019-08-01 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 537,077 17,903 3.45 98,489 3.13 0.1475
2019-05-08 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 519,174 16,768 3.34 95,502 14.71 0.1458
2019-02-01 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 502,406 10,202 2.07 83,254 -12.24 0.1448
2018-11-01 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 492,204 34,971 7.65 94,867 22.08 0.1403
2018-07-31 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 457,233 -44,008 -8.78 77,711 -4.87 0.1184
2018-05-11 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 501,241 12,868 2.63 81,692 11.62 0.1251
2018-02-02 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 488,373 36,133 7.99 73,188 6.44 0.1066
2017-11-09 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 452,240 18,513 4.27 68,759 23.02 0.1031
2017-08-01 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 433,727 22,057 5.36 55,894 24.16 0.0881
2017-05-05 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 411,670 18,884 4.81 45,016 55.57 0.0718
2017-02-08 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 392,786 -52,358 -11.76 28,937 -25.46 0.0488
2016-11-02 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 445,144 -247 -0.06 38,821 1.33 0.0672
2016-08-04 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 445,391 -19,698 -4.24 38,313 3.63 0.0695
2016-05-05 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 465,089 39,905 9.39 36,970 -30.90 0.0691
2016-02-04 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 425,184 47,550 12.59 53,501 36.04 0.1061
2015-11-12 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 377,634 58,300 18.26 39,327 -0.26 0.0774
2015-08-11 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 319,334 724 0.23 39,431 4.91 0.0704
2015-04-28 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 318,610 318,610 0.00 37,586 0.0678
2015-01-30 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -294,853 -100.00 0 -100.00
2014-11-06 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 294,853 6,227 2.16 33,115 21.18 0.0571
2014-08-12 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 288,626 31,200 12.12 27,327 50.11 0.0466
2014-05-09 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 257,426 11,800 4.80 18,205 -0.25 0.0331
2014-02-07 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 245,626 36,100 17.23 18,250 14.88 0.0341
2013-11-08 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 209,526 112,800 116.62 15,886 105.62 0.0316
2013-07-24 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 96,726 96,726 7,726 0.0166
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.